KRAS and non-small cell lung carcinoma: The prevalence of NSCLC patients with tumors having PD-L1 expression TPS ≥50% or high TMB was previously shown to be significantly higher with KRAS G12C mutations compared to all other KRAS mutations (G12A/D/V, G13, Q61), with the highest prevalence of TMB high seen in tumors with G13 mutations and lowest in G12D tumors (44).